4th International Conference on Vascular Dementia
University of California, USA
Title: Blood biomarkers in preclinical Alzheimer Disease
Biography: Howard J Federoff
Our group has studied a longitudinal cohort of seniors, >75 yrs, to discover and validate peripheral blood measures that canrnaccurately predict which cognitively normal subjects will progress to amnestic Mild Cognitive Impairment (aMCI) or Alzheimer disease (AD) in a three year period. We initially reported on plasma metabolites which are now more accurate as a diagnostic. We havernextended this work on plasma metabolomics and have discovered and validated a panel of 24 analytes that predict phenoconversionrnto Alzheimer’s disease with accuracy of >96%.